Isomorphic Labs and MSD team up on oncology small molecules: IsoDDE designs, MSD runs the wet lab
Isomorphic Labs and MSD announced a research collaboration to discover small-molecule therapeutic candidates against one oncology indication of strategic importance. Isomorphic Labs will run in silico predictions and supply molecular designs using its proprietary drug-design engine IsoDDE, which in this collaboration draws on high-quality proprietary datasets selected and provided by MSD; MSD will handle preclinical and clinical development, manufacturing and commercialization. The agreement includes an upfront payment, payments tied to research, development, regulatory and commercialization milestones, and tiered royalties on net sales, and Isomorphic Labs holds an option to co-fund development in exchange for higher royalties.